Financial Performance - The company's revenue for the first three quarters of 2025 reached 2.62 billion yuan, a year-on-year increase of 12.8% [3] - Net profit for the same period was 240 million yuan, up 2.5% year-on-year [3] - In Q3 alone, revenue was 860 million yuan, showing an 8.3% year-on-year growth, while net profit decreased by 3.9% to 60 million yuan [3] Channel Performance - Offline channels achieved a revenue of 1.36 billion yuan in Q3, with a year-on-year growth of 35.7% [3] - Revenue from peripheral provinces surged by 113.4% year-on-year, with Q3 offline channel revenue growing by 27.2%, and peripheral provinces seeing a 94.0% increase [3] - E-commerce channels faced a decline in revenue and operating profit due to public sentiment and platform strategy adjustments, but the company is actively taking measures to improve performance [3] Product Performance - Revenue from the company's health product line reached 251 million yuan, a 16.4% year-on-year increase, with significant growth in the probiotic and organic cotton series, which saw a 35.5% increase [4] - Health products now account for over 50% of total revenue, with organic cotton series revenue doubling year-on-year [6] Strategic Adjustments - The company plans to maintain investment in Douyin for brand exposure while increasing resource allocation to Xiaohongshu due to positive feedback [4] - Instant retail is viewed as a rapidly growing channel, with expectations for continued resource investment and increased market share [5] - The company aims to enhance brand influence and optimize product matrix to adapt to changes in e-commerce platforms [4] Future Outlook - The company is expanding its market presence in non-core provinces, with revenue growth exceeding 100% in peripheral markets [5] - Core provinces are expected to maintain stable growth, with potential for further improvement in net profit margins through optimized channel costs [5]

Investment Rating - The report assigns a "Buy" rating for the company, indicating a positive outlook for investment [5][9][42]. Core Viewpoints - The company is recognized as a leading domestic brand in the disposable hygiene products industry, focusing on the development, production, and sales of personal hygiene products, including sanitary napkins, baby diapers, and adult incontinence products [8][15]. - The company has established a strong market presence, with its "Free Point" brand ranking second among domestic sanitary napkin brands in terms of market share as of 2024 [8][15]. - The report highlights the company's competitive advantages built on a "channel + brand + R&D" strategy, emphasizing its focus on core markets and e-commerce expansion [23][28]. Financial Performance and Forecast - The company’s revenue is projected to grow from 21.44 billion RMB in 2023 to 32.54 billion RMB in 2024, with a year-on-year growth rate of 51.77% [7][42]. - The forecast for 2025 estimates revenue at 44.75 billion RMB, reflecting a growth rate of 37.52% [9][41]. - The net profit attributable to the parent company is expected to increase from 238 million RMB in 2023 to 384.87 million RMB in 2025, with a growth rate of 33.79% [7][42]. Market Strategy - The company employs a multi-channel sales strategy, including distributors, key accounts (KA), and e-commerce platforms, to enhance market penetration [24][25]. - The e-commerce channel is particularly emphasized, with revenue from this segment projected to grow significantly, contributing 46.9% of total revenue by 2024 [25][28]. - The company is actively expanding its market presence in peripheral provinces while maintaining a stronghold in its core markets of Sichuan, Chongqing, and Yunnan [28][29]. Product Development and R&D - The company is committed to continuous product innovation, focusing on high-end product lines and health-oriented series, such as the probiotic series [32][35]. - R&D investment is increasing, with a focus on developing new materials and enhancing product comfort and functionality [35][39]. - The company has introduced several new product lines aimed at improving consumer experience and expanding its market reach [35][36]. Valuation Comparison - The report compares the company with peers in the personal care sector, noting that its projected price-to-earnings (P/E) ratio for 2025 is 32.61, significantly lower than the average P/E of 63 for comparable companies [11][42][43]. - This valuation suggests potential upside for investors, given the company's strong market position and growth prospects [11][42].